NorthX Biologics. (7/3/23). "Press Release: NorthX Biologics, a Leading Nordic Development and Manufacturing Organisation Announces Acquisition of a Biologics Manufacturing Unit from Valneva". Matfors.

	Organisation	NorthX Biologics, biologics manufacturing unit Solna
	Group	NorthX Biologics Matfors AB
	Organisation 2	Valneva Sweden AB
	Group	Valneva (Group)
	Product	contract manufacturing (biologicals)
	Product 2	advanced therapeutic product (gene therapy, cell therapy, tissue engineering products)
	Person	Hoogstraate, Janet (NorthX Biologics 202307– before Valneva Sweden AB)
	Person 2	Strigård, Helena (NorthX Biologics 202307 CEO formerly Director General at SwedenBIO)

NorthX Biologics (‘NorthX’), a leading Nordic development and manufacturing organisation with a focus on advanced biologics, CGT (cell and gene therapy) and vaccines, announced today the successful acquisition of the Stockholm-based Clinical Trial Manufacturing unit from Valneva Sweden, significantly expanding capabilities.

The acquisition includes the transfer of a multi-purpose facility, situated in the Stockholm life science cluster, close to Karolinska University Hospital. In addition, 30 staff members who currently operate the facility will also join NorthX. The site and staff have a long history with extensive experience of serving both Valneva internally and also working with external customers on a contract development and manufacturing basis. With expertise in mammalian expression systems and viral vectors, the capabilities complement those of NorthX’s existing business of advanced microbial based manufacturing of proteins and plasmid DNA. The acquired unit excels in process development, scale up, GMP production, quality control analytics, and quality assurance/release and is capable of working with Biosafety Level (BSL) 2/2+ and BSL 3 organisms. With this expansion, NorthX enhances its capabilities and can offer comprehensive services to a wider range of clients globally.

Janet Hoogstraate, currently Managing Director of Valneva Sweden, will join the NorthX team. She commented, “I am very proud when looking back at what we have achieved within the unit over the past years and look forward with great enthusiasm to build on NorthX’s position as the go-to manufacturer of advanced biologics in Northern Europe.”

Helena Strigård, CEO of NorthX, said, “We are delighted to join forces with our new colleagues in Stockholm to bring new innovative treatments to tomorrow’s patients.”

Thomas Eldered, Chairman of NorthX, commented, “This strategic move marks a significant milestone in our growth journey and strengthens NorthX as Sweden’s Innovation Hub. We are now able to work with ATMPs and advanced biologics, including process development and manufacture for clinical trials and commercial requirements.”

FOR MORE INFORMATION, PLEASE CONTACT:

Helena Strigård
Chief Executive Officer, NorthX Biologics
E-mail: helena.strigard@nxbio.com

Aaron Small
Vice President – Sales and Corporate Development, NorthX Biologics
E-mail: aaron.small@nxbio.com

Janet Hoogstraate
Ex Managing Director, Valneva Sweden
E-mail: janet.hoogstraate@valneva.com

ABOUT NORTHX BIOLOGICS

NorthX Biologics develops and manufactures advanced biologics and has over 30 years of GMP production experience. The team provides process development and GMP manufacturing services with expertise in plasmid DNA, mRNA, proteins, cell therapy and other advanced biologics. Headquartered in the heart of Sweden, the team serves customers worldwide. In 2021 NorthX was recognised and appointed as the national innovation hub for GMP manufacture of advanced therapeutics and vaccines by the Swedish Government and Vinnova, Sweden's innovation agency. NorthX has the ambition to become a leading cell and gene therapy manufacturer and partner of choice for innovative drug development companies. For more information visit www.nxbio.com.

Record changed: 2024-01-20